On Saturday, November 19 Redwood Pharma AB will present at the conference ”Inspirationsträff för tjejer – Våga spara i aktier!” at the City Konferenscenter, Klostergatan 23 in Örebro between 09.30 and 16.00 hrs.
On Saturday, November 19 Aktiespararna is hosting a meeting to inspire women to invest in equities. Redwood Pharma’s product candidate RP101 is being designed to help this target segment who suffer from moderate to severe Dry Eye Disease. CEO Martin Vidaeus will present Redwood Pharma and its RP101 project and will be open to meet with interested investors and answer questions.
For more information about the conference visit:
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information see: www.redwoodpharma.com